Related by context. All words. (Click for frequent words.) 82 Phase IIb 82 Phase 2a 81 Phase 2a clinical 80 Phase IIa clinical 80 Phase IIa trial 80 Phase Ib 79 Phase 2b study 79 phase IIa 78 Phase 1b 78 phase IIa clinical 78 Phase IIb clinical 78 Phase IIb trial 77 Phase III clinical 77 Phase Ib clinical 76 phase IIb 76 Phase III 76 Phase 2a trial 76 Phase 2b trial 75 phase 2a 75 Phase 2b 74 Phase 2b clinical 74 Phase 1b clinical 73 pivotal Phase III 72 Phase II 72 Phase 1b trial 72 Phase Ib study 72 phase Ib 71 multiple ascending dose 71 phase IIb clinical 71 dose escalation trial 71 Phase III clinical trials 71 Phase 1a 70 dose escalation Phase 70 Phase IIIb clinical 70 confirmatory Phase III 70 Phase Ia 70 clinical trial 69 Phase IIb trials 69 Phase #b/#a 69 Phase III trials 69 Phase IIa trials 69 double blind placebo 68 NGX# 68 Phase 1a clinical 68 Phase IIIb 68 dose escalation study 68 PRX # 68 pivotal Phase 68 Phase #/#a 68 Phase IIB 68 placebo controlled Phase 68 placebo controlled 67 phase IIb trial 67 Phase 2b clinical trials 67 placebo controlled clinical 67 Phase Ib II 67 cannabinor 67 Phase III pivotal 67 APEX PD 67 phase IIb study 66 NP2 Enkephalin 66 randomized Phase IIb 66 INCB# [001] 66 preclinical 66 multicenter Phase II 66 GALNS 66 JAK inhibitor 66 pharmacokinetic 66 Fx #A 66 single ascending dose 65 KRN# 65 ISIS # 65 ADVANCE PD 65 multicenter Phase 65 preclinical studies 65 Phase IIb clinical trials 65 placebo controlled Phase III 65 Cloretazine R VNP#M 65 pharmacokinetic studies 65 AeroLEF TM 65 randomized Phase III 65 QLT# 65 diabetic neuropathic pain 65 registrational 65 confirmatory Phase 3 64 AZILECT R 64 dose escalation clinical 64 tolerability 64 pharmacokinetic PK 64 phase Ib clinical 64 dyskinesia PD LID 64 randomized controlled Phase 64 bicifadine 64 pharmacokinetics PK 64 Phase IIb Trial 64 IIa trial 64 blinded randomized placebo controlled 64 Phase III Clinical Trial 64 PSN# [002] 64 Mipomersen 64 alvimopan 64 Traficet EN 64 randomized multicenter 64 Zenvia Phase III 64 COMFORT II 64 Phase IIa clinical trials 64 Phase #b/#a trial 64 VEGF Trap 64 elotuzumab 64 Phase IIa proof 63 phase IIIb 63 Phase 2a clinical trials 63 Phase Ib clinical trials 63 fostamatinib 63 multicenter randomized Phase 63 Phase III randomized controlled 63 R#/MEM # 63 Phase IIIb study 63 randomized Phase 63 ocrelizumab 63 alvespimycin 63 double blinded placebo 63 ganetespib 63 PD LID 63 ADX# 63 glufosfamide 63 Pivotal Phase III 63 HuMax EGFr 63 Phase Ib IIa 63 safety tolerability 63 Archexin 63 Phase III ALLEGRO 63 BCX# 63 Parkinson disease levodopa induced 63 pharmacokinetic PK study 63 RDEA# 63 Phase 63 LCP AtorFen 63 oral prodrug 63 FOLOTYN ® 63 teduglutide 63 clinical trials 63 RSD# oral 63 Phase III placebo controlled 63 ENDEAVOR IV 63 preclinical efficacy 63 II Clinical Trial 62 HGS# 62 NO# [002] 62 initiate Phase 62 IND enabling 62 Sym# 62 dose escalation 62 randomized placebo controlled 62 ADAGIO study 62 Dacogen injection 62 aclidinium bromide 62 PXD# 62 multicenter randomized placebo controlled 62 tezampanel 62 BRIM3 62 multicenter 62 velafermin 62 MEND CABG 62 Phenoptin 62 riociguat 62 BRIM2 62 AEGR 62 initiate Phase IIb 62 Phase III Trial 62 huC# DM4 62 AIR CF1 62 investigational compound 62 relapsed multiple myeloma 62 Phase IIb Clinical Trial 62 Cloretazine ® 62 Phase IIb III 62 Corlux 62 PEG PAL 62 Initiate Phase 62 double blinded randomized 62 European Sepsis Trial 62 Phase III Pivotal 62 oral formulation 62 Phase IIA 62 randomized double 62 fosbretabulin 62 masked placebo controlled 62 clinical pharmacology studies 62 Ocrelizumab 62 Aplidin 62 Phase 2b Clinical Trial 62 Initiated Phase 62 ANAVEX #-# [003] 62 HGS ETR1 62 ongoing Phase 1b 62 relapsed refractory multiple myeloma 62 Phase 2a proof 62 Triolex 62 Pivotal Phase 62 pharmacodynamic PD 61 TMC# C# 61 INCB# [002] 61 vidofludimus 61 DDP# 61 CRLX# 61 CR# vcMMAE 61 ascending dose 61 elacytarabine 61 selective androgen receptor modulator 61 rALLy clinical trial 61 CB2 selective receptor agonist 61 ILLUMINATE 61 trodusquemine 61 brivaracetam 61 TAXUS ATLAS 61 ascending doses 61 label dose escalation 61 PDE4 inhibitor 61 blind randomized placebo 61 Pivotal Trial 61 Oglemilast 61 prospective multicenter randomized 61 multicenter clinical 61 phase IIb III 61 dose cohorts 61 TBC# 61 MAP# 61 pivotal bioequivalence 61 Alzhemed TM 61 GAMMAGARD 61 ATL# [001] 61 MERLIN TIMI 61 lomitapide 61 Safinamide 61 dirucotide 61 Phase 1b clinical trials 61 multicentre randomized 61 Amrubicin 61 Carfilzomib 61 deforolimus 61 Phase III confirmatory 61 dose dose escalation 61 CEQ# 61 Bicifadine 61 safinamide 61 EOquin 61 GLP toxicology studies 61 randomized controlled 61 dexpramipexole 61 Phase 2b kidney transplant 61 investigational drug 61 LEVADEX 61 DermaVir Patch 61 randomized Phase 2b 61 Onrigin 61 rALLy trial 61 Phase #b/#a clinical 61 oral ridaforolimus 61 multicenter Phase III 61 Phase III randomized 61 HuMax CD4 61 multicenter phase 61 TG MV 61 Cimzia ® certolizumab pegol 61 multicenter placebo controlled 61 incyclinide 61 TMC# [002] 61 opioid induced bowel dysfunction 61 forodesine 61 denufosol 61 neurogenic orthostatic hypotension 61 AZILECT ® 61 Investigational Device Exemption IDE 61 midstage trials 61 TRO# 61 IMGN# 61 placebo controlled randomized 60 Phase III Clinical Trials 60 rNAPc2 60 mipomersen 60 methylnaltrexone 60 IIa clinical 60 rilonacept 60 Aurexis 60 mGluR5 negative 60 PHX# 60 Randomized Phase 60 dosing cohort 60 Gabapentin GR 60 eltrombopag 60 ZYBRESTAT fosbretabulin 60 Phase 2b monotherapy 60 Pivotal Study 60 mGluR5 NAM 60 initiate Phase 1b 60 Annamycin 60 SPIRIT FIRST 60 laquinimod 60 virus HCV protease inhibitor 60 PRECiSE 60 pharmacokinetics 60 ganaxolone 60 dosing cohorts 60 EndoTAG TM -1 60 nonclinical studies 60 label multicenter 60 Phase 2b randomized 60 PFO migraine 60 teriflunomide 60 bardoxolone 60 NOX E# 60 cancer neuroendocrine tumor 60 multicenter randomized double 60 confirmatory clinical 60 DASISION 60 PEG Interferon lambda 60 blinded placebo controlled 60 Factor VIIa 60 TASKi2 60 initiate Phase 2b 60 IIa clinical trial 60 TACI Ig 60 aclidinium 60 PREOS 60 darusentan 60 GLPG# 60 Desmoteplase 60 Cloretazine 60 pomalidomide 60 Tanespimycin 60 subcutaneously administered 60 RhuDex 60 PS# [001] 60 EchoCRT 60 prucalopride 60 GATTEX 60 ALKS 60 Phase III psoriasis 60 Azedra 60 GetGoal Phase III 60 tanespimycin 60 Plicera 60 MLN# 60 AQ4N 60 ELACYT 60 Cimzia ® 60 DR Cysteamine 60 Cannabinor 60 OncoGel 60 huN# DM1 60 Golimumab 60 davunetide intranasal AL 60 RSD# 60 CG# [003] 60 IMA# 60 Ostarine 60 Meets Primary Endpoint 60 histone deacetylase HDAC inhibitor 60 registrational trial 60 AEG# 60 Aclidinium 60 prospective multicenter 60 Elagolix 60 dose cohort 60 Phase 2a Clinical Trial 60 HuMax CD# 60 reslizumab 59 Locteron ® 59 Zerenex 59 receptor tyrosine kinase inhibitor 59 investigational humanized monoclonal antibody 59 pharmacodynamic profile 59 OXi# 59 pertuzumab 59 intranasal formulation 59 carfilzomib 59 Omacetaxine 59 enzastaurin 59 ZYBRESTAT 59 Hsp# Inhibitor 59 efficacy endpoint 59 Ophena TM 59 active comparator 59 AIR CF2 59 Vicriviroc 59 octreotide implant 59 nalbuphine ER 59 Tezampanel 59 RhuDex ® 59 Zenvia TM 59 oral rivaroxaban 59 controlled multicenter 59 elagolix 59 Phase 1b dose escalation 59 CIMZIA TM 59 SNT MC# 59 BLA submission 59 ABSORB trial 59 Spiegelmer ® 59 Darusentan 59 Phase 2b Trial 59 Alocrest 59 Zenvia ™ 59 IIb clinical trial 59 interferon beta 1b 59 LymphoStat B TM 59 Inhalation Solution 59 viral kinetic 59 ularitide 59 Acute Ischemic Stroke 59 LUMINATE 59 Marqibo 59 Denufosol 59 mertansine 59 ruxolitinib 59 Microplasmin 59 pharmacodynamic 59 PRT# 59 refractory CLL 59 preclinical toxicology 59 safety tolerability pharmacokinetics 59 MEK inhibitor 59 midstage clinical 59 cell lymphoma CTCL 59 LUX Lung 59 RGB # 59 acyclovir Lauriad R 59 Relovair 59 subcutaneous formulation 59 NLX P# 59 Dapagliflozin 59 AVN# [001] 59 lintuzumab 59 Daclizumab 59 VNP#M 59 KNS # 59 generation purine nucleoside 59 investigational 59 Laquinimod 59 randomized clinical 59 GATTEX TM 59 zanolimumab 59 label multicenter Phase 59 Phase III multicenter 59 treatment naive genotype 59 evaluating tivozanib 59 eprotirome 59 Aryplase 59 Ozarelix 59 sapacitabine 59 baminercept 59 APPRAISE 59 JAK2 inhibitor 59 Augment Injectable 59 Icatibant 59 CRx 59 prospective observational 59 investigational pan BCR 59 OHR/AVR# 59 axitinib 59 compound INCB# 59 Multiple Ascending Dose 59 ENDEAVOR II 59 YONDELIS 59 Phase 2a Trial 59 ACOMPLIA R 59 MGCD# [001] 59 vivo preclinical 59 Enobia 59 Zybrestat 59 ACTEMRA TM 59 PROMACTA 59 urocortin 2 59 Zoraxel 59 PRESEPT 59 Serdaxin 59 HCV SPRINT 58 SCH # 58 subanalysis 58 MBP# [001] 58 Elocalcitol 58 Sapacitabine 58 Locteron 58 unblinded 58 randomized blinded 58 obatoclax 58 Feasibility Trial 58 romidepsin 58 pharmacokinetic pharmacodynamic 58 ALN TTR# 58 ProSavin 58 administered subcutaneously 58 ICA # 58 INT# [002] 58 PDX pralatrexate 58 IPL# 58 BAY #-# 58 Pimavanserin 58 dacetuzumab 58 stated Michelle Berrey 58 Keryx Biopharma 58 Kahalalide F 58 Pharmacokinetic Study 58 lorvotuzumab mertansine 58 Urocortin 2 58 LibiGel ® 58 Phase IIa Clinical Trial 58 ORMD 58 cystinosis patients 58 Synavive 58 IL# PE#QQR 58 IMC A# 58 lixisenatide 58 Lu AA# 58 ENDEAVOR III 58 pharmacodynamics 58 OncoVEX GM CSF 58 eculizumab 58 sunitinib malate 58 perifosine 58 AMD# [003] 58 Bronchitol 58 IND submission 58 AP# [003] 58 OMNARIS HFA 58 XL# XL# XL# 58 Lodotra TM 58 miconazole Lauriad ® 58 oral treprostinil 58 multicenter prospective 58 REVIVE Diabetes 58 SUCCEED trial 58 unblinding 58 Androxal TM 58 initiate Phase IIa 58 ARRY 58 varespladib 58 Exherin TM 58 CDP# 58 HGS ETR2 58 omacetaxine mepesuccinate 58 Amigal 58 prospective randomized multicenter 58 ofatumumab 58 PREOS R 58 galiximab 58 omacetaxine 58 OPT CHF 58 pharmacokinetic profile 58 severe hypercholesterolemia 58 EOquin TM 58 Tyrima 58 trial evaluating PRX# 58 oral FTY# 58 prospective randomized placebo 58 RG# [001] 58 MAGE A3 ASCI 58 Pharmacokinetic PK 58 bortezomib Velcade 58 Clinical Trial 58 torezolid phosphate 58 diarrhea predominant irritable 58 Fibrillex TM 58 BETAS 58 peginesatide 58 LCP Tacro 58 Pharmacokinetic 58 Blinatumomab 58 thorough QT 58 Tarceva TM 58 CLL8 58 CYT# 58 ITAX 58 HCD# [002] 58 Omnitarg 58 celgosivir 58 multicenter randomized controlled 58 edoxaban 58 Firazyr 58 IDX# 58 cathepsin K inhibitor 58 preclinically 58 Zelrix 58 Preclinical 58 eosinophilic asthma 58 Dextofisopam 58 ELND# 58 prospective randomized 58 visilizumab 58 p# inhibitor 58 MEND CABG II 58 XL# [003] 58 Nasulin 58 Xanafide 58 Trofex 58 ofatumumab HuMax CD# 58 analgesic efficacy 58 dexanabinol 58 aflibercept 58 ThGRF 58 IIa trials 58 blind randomized 58 IPX# 58 Milnacipran 58 GRN# 58 ulimorelin 58 nonrandomized 58 ANG# 58 Menerba 58 NVA# 58 dose escalation phase 58 cediranib 58 investigational oral 58 ORACLE MS 58 placebo controlled studies 58 Luveniq 58 RoACTEMRA 58 Clinical Study 58 pradefovir 58 cetrorelix 58 BNC# 58 Capesaris 58 AEZS 58 Phase #/#a trial 58 CUSTOM III 58 generation PNP inhibitor 58 atacicept 58 tezampanel NGX# 58 PNP inhibitor 58 initiate Phase Ib 58 Opexa 58 Fentanyl TAIFUN R 58 Diabetic Macular Edema 58 Prodarsan ® 58 Guanilib 58 SAR# [004] 58 Naproxcinod 58 TOLAMBA 58 rasagiline tablets 58 CCX# 58 ANCHOR trial 58 LymphoStat B 58 Dalbavancin 58 mGluR2 positive 58 LEVADEX ™ 58 Dyloject TM 58 GSK# [002] 58 TG# [003] 58 vascular disrupting agent 58 CLORETAZINE TM VNP#M 58 Enzastaurin 58 Civacir 57 albinterferon alfa 2b 57 non nucleoside inhibitor 57 Ceflatonin 57 seliciclib CYC# 57 multicenter randomized 57 Pirfenidone 57 ASSERT trial 57 CCX# B 57 afatinib 57 Vilazodone 57 allosteric modulator NAM 57 New Drug IND 57 ILUVIEN ® 57 Iloperidone 57 MEK inhibitor RDEA# 57 Zingo TM 57 antibody MAb 57 HQK 57 pegloticase 57 Betaferon ® 57 Cimzia TM 57 randomized controlled clinical 57 Investigational 57 pseudobulbar affect PBA 57 Evoltra 57 dimebon 57 microplasmin 57 Azedra TM 57 Completes Patient Enrollment 57 oxypurinol 57 LUVENIQ 57 placebo controlled clinical trials 57 Gattex 57 neratinib 57 OvaRex R 57 biologic therapy 57 cariprazine 57 RH1 57 Panzem R 57 PRIMO CABG 57 Diamyd ® 57 Troxatyl 57 Ventavis 57 GLYX 57 PF # [001] 57 zileuton 57 Sigma Tau SpA 57 Panzem R NCD 57 humanized anti 57 CA4P 57 rALLy 57 tiapamil 57 topical formulation 57 Serada 57 Novolimus 57 tafamidis 57 NUVIGIL 57 Pharmacokinetics PK 57 ARIKACE 57 TG# [001] 57 volociximab 57 Kamada AAT 57 Tesetaxel 57 Marketing Authorization Application 57 Personalized Immunotherapy 57 afamelanotide 57 Maximum Tolerated Dose 57 daclizumab 57 resminostat 57 anticancer compound 57 SRT# [003] 57 AVADO 57 BLA filing 57 docetaxel Taxotere R 57 Ofatumumab 57 Phase III Trials 57 MAA submission 57 inhaled formulation 57 randomized controlled multicenter 57 MOZOBIL 57 StemEx 57 preclinical pharmacokinetic 57 ocular formulation 57 APTIVUS 57 Spheramine 57 Empatic 57 Santhera 57 Tarvacin TM 57 randomized multicenter trial 57 CCR5 antagonist 57 Alfimeprase 57 Eltrombopag 57 Forodesine HCl 57 Atiprimod 57 6R BH4 57 prospective randomized controlled 57 Phase III HEAT 57 ASA# 57 atrasentan 57 crofelemer 57 VA# [002] 57 Symadex 57 EVIZON 57 severe gastroparesis 57 peripherally acting 57 secondary efficacy endpoints 57 CAMMS# 57 Phase 2b Study 57 PEG SN# 57 pharmacodynamic effects 57 BAL# [002] 57 Aflibercept 57 Study Evaluating 57 Hyphanox 57 SinuNase TM 57 oral dosing 57 GATTEX ™ 57 ozarelix 57 Tamibarotene 57 AIR CF3 57 CoFactor 57 AeroLEF 57 metaglidasen 57 Ceflatonin R 57 EFAPROXYN 57 Oral NKTR 57 REG2 57 coadministration 57 nucleotide analog 57 novel VDA molecule 57 unique alkylating agent 57 ASCEND HF 57 CD# CEA 57 IND Investigational New 57 PEARL SC 57 CRMD# 57 Clolar ® 57 voreloxin 57 CLARITY study 57 EGS# 57 Phase 2a Study 57 multicentre randomized double 57 CCR5 mAb 57 lumiliximab 57 Alvesco R 57 indacaterol 57 pafuramidine 57 AZX# 57 Degarelix 57 treatment naïve genotype 57 adipiplon 57 Memryte 57 ecallantide 57 OvaRex ® MAb 57 fluticasone furoate 57 ACTEMRA 57 TKM ApoB 57 apremilast 57 fidaxomicin Phase 3 57 tolerated dose MTD 57 PRTX 57 Ereska 57 relapsed myeloma 57 Phase IIa Trial 57 IMC #B 57 ATACAND 57 histamine dihydrochloride 57 SILENOR TM 57 MAXY alpha 57 Clonicel 57 BrachySil TM 57 RRMS patients 57 trastuzumab emtansine T DM1 57 ALN RSV# 57 Trial Evaluating 57 tasimelteon 57 Marketing Authorisation Application 57 LY# [003] 57 CLIRS trial 57 nalmefene 57 GEM OS1 57 SinuNase 57 generation proteasome inhibitor 57 phase III ACCLAIM 57 painful diabetic neuropathy 57 nitazoxanide 57 OLYMPIA registry 57 nab paclitaxel 57 acute decompensated heart 57 HCV RESPOND 2 56 Stedivaze 56 STRIDE PD 56 blind placebo controlled 56 budesonide foam 56 injectable formulation 56 SAR# [002] 56 INCB# [003] 56 ToGA 56 Restanza 56 Phase III VISTA 56 lorcaserin Phase 56 ABSORB clinical 56 TASKi3 56 Cethrin 56 EXPAREL ™ 56 LibiGel Phase III 56 tgAAC# 56 ThermoDox ® 56 tolerability pharmacokinetics 56 ritonavir boosted 56 Plenaxis TM 56 ATL/TV# 56 Crofelemer 56 oral renin inhibitor 56 Patient Enrollment 56 Triapine 56 PRE SURGE 56 label multicenter randomized 56 oxymorphone ER 56 Initiates Phase II 56 Phase Ib Clinical Trial 56 alemtuzumab Campath 56 VITAL Trial 56 acyclovir Lauriad ® 56 ataluren 56 Northera 56 tolerability profile 56 blinded randomized 56 oral methylnaltrexone 56 relapsing multiple sclerosis 56 dextromethorphan quinidine 56 multicentre 56 Initiates Phase III 56 TLK# 56 TRV# [001] 56 bendamustine 56 Glybera R 56 AVE# 56 REVEAL Registry 56 CHAMPION PCI 56 BIBW 56 NKTR 56 Raptiva ® 56 safety tolerability pharmacokinetic 56 CIMZIA TM certolizumab pegol 56 ProLindac 56 Marketing Authorization Application MAA 56 trabedersen 56 UPLYSO 56 Matrix Phase 2b 56 Pazopanib 56 Arikace 56 randomized discontinuation trial 56 arzoxifene 56 Loramyc R 56 GEM OS2 56 PANVAC VF 56 Pivotal Trials 56 Thiarabine 56 rHuPH# 56 labial herpes 56 Preclinical studies 56 FTY# fingolimod 56 Pivotal Clinical Trial 56 desvenlafaxine succinate 56 Orazol 56 ONCONASE R 56 Clinical Trial Results 56 Phase IIb kidney transplant 56 relapsing remitting multiple sclerosis 56 Rebif ® 56 eniluracil 56 Prosaptide 56 prospective multicentre 56 Initiates Clinical 56 bosutinib 56 Tasimelteon 56 linaclotide 56 refractory metastatic colorectal cancer 56 SUTENT ® 56 Azixa 56 sorafenib Nexavar 56 M6G 56 Urocidin 56 Phase #/#a clinical 56 mTOR inhibitor 56 Quinamed 56 Serdaxin ® 56 NDA submission 56 pharmacodynamic properties 56 multicenter multinational 56 refractory gout 56 MIRCERA 56 mapatumumab 56 investigational hepatitis C 56 clazosentan 56 Phase IIB clinical 56 Tocosol Paclitaxel 56 HER2 positive metastatic breast 56 CIMZIA ™ 56 Sular formulation 56 liposomal formulation 56 PSMA ADC 56 Double Blind Placebo 56 EVEREST II 56 IAP inhibitor 56 Clinical Antipsychotic Trials 56 ponatinib 56 Relivar 56 GRN#L 56 next generation URAT1 56 Adalimumab 56 depsipeptide 56 L BLP# 56 efficacy tolerability 56 pharmacodynamics PD 56 DU #b 56 TEMSO 56 Valdoxan 56 ORENCIA ® 56 efficacy 56 REOLYSIN ® 56 Debio 56 PA# [002] 56 dosage regimens 56 almorexant 56 FIRMAGON R 56 catheter occlusion 56 iSONEP 56 dose titration 56 OMP #M# 56 TELINTRA 56 initiated Phase Ib 56 PROPEL trial 56 dirucotide MBP# 56 Nexavar sorafenib 56 Æterna Zentaris 56 Diamyd R 56 Prospective Randomized 56 angiogenesis inhibitor 56 Bezielle 56 GSK# [001] 56 canakinumab 56 Chemophase 56 novel oral anticoagulant 56 Linaclotide